Table 3 Chemokine receptor engineering to improve NK cell migration
From: Development of NK cell-based cancer immunotherapies through receptor engineering
Receptor | Target | NK sources | Modification techniques | Target disease | Outcomes | Ref |
|---|---|---|---|---|---|---|
CXCR1 | IL-8 | PB | mRNA electroporation | Ovarian cancer | Greater chemiotaxis in vivo Increased tumor control | [123] |
CXCR2 | CXCL5 | PB | Retroviral vector | Renal cell carcinoma | Greater chemiotaxis in vitro Increase target cell killing and adhesion in vitro | [120] |
CXCR2 | CXCL1-3 and CXCL5-8 | NK92 | CRISPR-Cas9 | Human Colon Cancer | Greater chemiotaxis in vivo into tumor sites Stronger cell-killing and proliferation activity Tumor reduction Increased survival | [122] |
CCR2B and CCR4 | CCL22 or CCL2 | NK-92 and PB | Lentiviral vector | None | Greater chemiotaxis in vitro | [130] |
CXCR4 | CXCL12 and SDF-1α | YTS | Lentiviral vector | Glioblastoma | Greater chemiotaxis in vitro and in vivo Tumor reduction/clearance Increased survival | [68] |
CXCR4 | SDF-1α | PB | Lentiviral vector | None | Greater chemiotaxis in vitro | [126] |
CXCR4R334X | SDF-1α | PB | mRNA transfection | None | Greater chemotaxis in vitro Increased the bone marrow homing | [125] |
CXCR4 and CCR7 | CXCL12 and CCL21 | NK92 | Lentiviral vector | Colorectal cancers | Tumor reduction Increased survival | [127] |
CCR5 | CCL5 | PB | Lentiviral vector | Human Colon Cancer | Greater chemiotaxis in vitro and in vivo | [132] |
CCR7 | CCL19 and CCL21 | PB | Trogocytosis | None | Greater chemotaxis in vitro Increased the lymph node homing | [129] |
CCR7 | CCL19 and CCL21 | NK-92 | DNA transfection | B-cell lymphoma | Greater chemiotaxis in vitro and in vivo Increased tumor control Increased survival | [128] |
CCR7 | CCL19 | PB | mRNA electroporation | None | Greater chemiotaxis in vitro | [109] |
